The abstract is read at the publisher; the summary is JClub's.
Integrated trial designs for alcohol-associated hepatitis (AH) are proposed to target both hazardous alcohol use and liver injury, using a composite primary endpoint spanning both outcome domains.
- Why it matters: AH has high morbidity and mortality, with no approved therapies, and alcohol misuse is not directly targeted in existing AH clinical trials. Because return to drinking affects recurrence risk and long-term survival, trials need to address both components together.
- What they did: The article outlines conceptual design challenges and approaches for integrated AH trials, and explains the rationale for a composite endpoint combining liver- and alcohol-related outcomes. It applies these ideas to the Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) trial design.
- The result: The ITAALD trial framework enables simultaneous evaluation of interventions aimed at alcohol misuse and liver injury, using a composite primary endpoint to reflect both sets of clinical consequences. This supports more directly aligned testing for AH than liver-only or alcohol-only designs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.